FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

Sarcoma Education
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident.
Visit Page
What is Sarcoma?

Sarcoma Subtypes

2026 Sarcoma Statistics

Webinars, Conferences & Discussions

Sarcoma Subtypes

What is Sarcoma?
Research
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident.
Visit Page
Latest Sarcoma Research

Funding Opportunities

Funded Research

SFA Research Grants

The Last Mile Sarcoma Research Award
Support & Resources
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident.
Visit Page
Treatment Centers

Sarcoma Clinical Trials

Information & Links

Clinical Trials Assistance

Patient Stories

Treatment Centers

Clinical Trials
Get Involved
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident.
Visit Page
Sarcoma Advocacy

Sarcoma Ambassadors

Research Advocacy

Sarcoma Awareness Month

SFA Ally

Sarcoma Advocacy Weekend

SFA Ally
Ways to Help
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident.
Visit Page
Sunflower Society

Support SFA

Fund Research

Donate Today

Volunteer

Honor & Memorial Giving

Seeds of Hope

Participate in an Event

Sarcoma Store

Stand Up to Sarcoma Gala

Honor & Memorial Giving

Donate

Main Content

FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

Read the story

Author

Carl Haddock

Main Content

FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

FDA Grants Orphan Drug Designation to Elraglusib for Soft Tissue Sarcomas

Author

section

Sign Up to Our Mailing List